The authors demonstrated that the inhibition of IL6R signaling by tocilizumab prevented osteosarcoma metastasis formation and suggested that TGFβ-blocking agents could be tested as new therapeutic options for osteosarcoma patients (99). Here, IL6R is linked to osteosarcoma.